Table 1 Effect of the experimental mutation of one or more amino acid(s) of ACE2 on the biological properties of the protein

24 – 26

QAK → KAE: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

31

K → D: Abolishes interaction with SARS-CoV spike glycoprotein

1

37

E → A: No effect on interaction with SARS-CoV spike glycoprotein

1

38

D → A: No effect on interaction with SARS-CoV spike glycoprotein

1

41

Y → A: Strongly inhibits interaction with SARS-CoV spike glycoprotein

1

68

K → D: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

82 – 84

MYP → NFS: Inhibits interaction with SARS-CoV spike glycoprotein

1

110

E → P: No effect on interaction with SARS-CoV spike glycoprotein

1

135 – 136

PD → SM: No effect on interaction with SARS-CoV spike glycoprotein

1

160

E → R: No effect on interaction with SARS-CoV spike glycoprotein

1

169

R → Q: About 95% loss of angiotensin I cleavage

2

192

R → D: No effect on interaction with SARS-CoV spike glycoprotein

1

219

R → D: No effect on interaction with SARS-CoV spike glycoprotein

1

239

H → Q: No effect on interaction with SARS-CoV spike glycoprotein

1

271

W → Q: About 95% loss of angiotensin I cleavage

2

273

R → Q: Complete loss of enzyme activity. Does not affect the amino acid transport activity of SLC6A19

3, 4

309

K → D: No effect on interaction with SARS-CoV spike glycoprotein

1

312

E → A: No effect on interaction with SARS-CoV spike glycoprotein

1

324

T → A: No effect on interaction with SARS-CoV spike glycoprotein

1

338 – 340

NVQ → DDR: No effect on interaction with SARS-CoV spike glycoprotein

1

345

H → A: Complete loss of enzyme activity

3

350

D → A: No effect on interaction with SARS-CoV spike glycoprotein

1

353

K → H, A or D: Abolishes interaction with SARS-CoV spike glycoprotein

1

355

D → A: Strongly inhibits interaction with SARS-CoV spike glycoprotein

1

357

R → A: Strongly inhibits interaction with SARS-CoV spike glycoprotein

1

359

L → K or A: No effect on interaction with SARS-CoV spike glycoprotein

1

383

M → A: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

389

P → A: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

393

R → A: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

425 – 427

SPD → PSN: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

465 – 467

KGE → QDK: No effect on interaction with SARS-CoV spike glycoprotein

1

481

K → Q: About 80% loss of angiotensin I cleavage

2

505

H → A: Complete loss of enzyme activity

3

514

R → Q: About 50% loss of angiotensin I cleavage but twofold greater activity with angiotensin II

2

559

R → S: Slightly inhibits interaction with SARS-CoV spike glycoprotein

1

603

F → T: No effect on interaction with SARS-CoV spike glycoprotein

1